Home > Rheumatology > EULAR 2022 > IL-6 inhibition successful in treating polymyalgia rheumatica

IL-6 inhibition successful in treating polymyalgia rheumatica

Presented By
Prof. Bhaskar Dasgupta, Anglia Ruskin University, UK
EULAR 2022
Phase 3, SAPHYR
Sarilumab demonstrated positive results in the randomised, phase 3 SAPHYR trial for patients with polymyalgia rheumatica (PMR). Significantly more participants reached sustained remission and the risk of flares was reduced. As IL-6 plays an important role in PMR, IL-6 inhibition with sarilumab was worth exploring [1]. By now, research has advanced to the phase 3, randomised, double-blind SAPHYR (NCT03600818) trial. The study included PMR patients ≥50 years who had at least 1 flare within 12 weeks before the trial while being on ≥7.5 mg of prednisolone. The study aimed to enrol 280 patients but recruited halted at 118 participants due to the COVID-19 pandemic. Participants were allocated to either placebo plus 52-week glucocorticoid [GC] taper or sarilumab 200 mg every 2 weeks plus 14-week taper of GC. The primary endpoint was defined as the rate of patients ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on